Meeting Summary
This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biological basis for targeting this process in oncology, delivered by Prof Calvert. This was followed by a discussion from Prof Pujade-Lauraine that focussed on patient selection for PARP inhibition and the role for these agents in BRCA -mutated and BRCA -like cancers. Next, Prof Colombo presented a clinical scenario of BRCA -associated ovarian cancer and examined optimal treatment options in the first-line setting and for progressive disease. She also highlighted current clinical data and ongoing trials evaluating PARP inhibition in advanced ovarian cancer. Prof Tutt then discussed the potential role for PARP inhibitors in patients with breast cancer, focussing on a clinical scenario of triple-negative disease and emphasising current and investigational treatment options. Lastly, Prof Van Cutsem described emerging data and ongoing clinical studies evaluating PARP inhibition in the treatment of patients with pancreatic and gastric cancers, and how this could impact future clinical practice. The programme also included a PARP quiz, in which participants were polled at the beginning and conclusion of the symposium to examine their knowledge and practice patterns regarding the use of PARP inhibitors in oncology. The key highlights from these presentations and the PARP quiz are summarised herein.
Please view the full content in the pdf above.
